Figure 2 from Discovery and Evaluation of Biomarkers for Triple-Negative Breast Cancer Subtypes Uncovers Patient Stratification and Targeted Therapeutic Strategies

<p>Histologic expression of basal markers in HR-positive breast tumors at different tumor stages. <b>A,</b> Representative sections of HR-positive samples at different tumor stages (LGDCIS, DCIS, and IDC) stained with the indicated basal markers. Scale bar, 50 μm. <b>B,</b> Bar plots representing the percentage of cells expressing each marker in in HR-positive samples across the different tumor stages. Statistics calculated two-way ANOVA. *, <i>P</i> < 0.05; **, <i>P</i> < 0.005; ns, not significant.</p>